the paradigm of il-6 from basic science to medicineil - 6从基础科学到医学的模式.pdfVIP

Available online /content/4/S3/S233 Supplement Review The paradigm of IL-6: from basic science to medicine Tetsuji Naka*, Norihiro Nishimoto† and Tadamitsu Kishimoto‡ *Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan †Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Japan ‡Osaka University, Japan Correspondence: Tetsuji Naka, Department of Molecular Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka Suita City, Osaka, 560-0871 Japan. Tel: +81 6 6879 4143; fax: +81 6 6879 4143; e-mail: naka@imed3.med.osaka-u.ac.jp Received: 12 February 2002 Arthritis Res 2002, 4 (suppl 3):S233-S242 Revisions requested: 13 February 2002 This article may contain supplementary data which can only be found Revisions received: 1 March 2002 online at /content/4/S3/S233 Accepted: 6 March 2002 © 2002 BioMed Central Ltd Published: 9 May 2002 (Print ISSN 1465-9905; Online ISSN 1465-9913) Chapter summary IL-6 is a pleiotropic cytokine with a wide range of biological activities in immune regulation, hematopoiesis, inflammation, and oncogenesis. Its activities are shared by IL-6-related cytokines such as leukemia inhibitory factor and oncostatin M. The pleiotropy and redundancy of IL-6 functions have been identified by using a unique receptor system comprising two functional proteins: an IL-6 receptor (IL-6R) and gp130, the common signal transducer of cytokines related to IL-6. Signal